Premium
Vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women: A randomized controlled trial
Author(s) -
Bunnasathiansri Soysuwan,
Herabutya Yongyoth,
OPrasertsawat Pratak
Publication year - 2004
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2004.00190.x
Subject(s) - medicine , misoprostol , curettage , placebo , cervical dilatation , curette , incidence (geometry) , obstetrics , abortion , gynecology , cervix , surgery , pregnancy , genetics , alternative medicine , pathology , cancer , optics , biology , physics
Aim: To investigate the efficacy of vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women. Methods: Forty‐four postmenopausal women with indication for dilatation and curettage were randomly assigned to receive either 400 µg of misoprostol or placebo vaginally 6 h before dilatation and curettage. The main outcome measures were the number of women who required cervical dilatation, cervical width, time taken to dilate to Hegar 6 and other complications. Results: The mean cervical diameter (4.59 millimeters in the misoprostol group vs 4.41 millimeters in the placebo group) was comparable between the two groups. A similar number of women in the misoprostol group and in the placebo group required cervical dilatation (12 vs 16, P = 0.35). The operative times for both groups were similar. The incidence of side‐effects was comparable in both groups. There were two uterine perforations in the misoprostol group (2 vs 0). Conclusion: There was no significant benefit from applying 400 µg vaginal misoprostol 6 h prior to dilatation and curettage in postmenopausal women.